Advanced Search
Korean J Pediatr 2013 March;56(3) :130-134.
Published online 2012 October 22.       
Vascular endothelial dysfunction after anthracyclines treatment in children with acute lymphoblastic leukemia
Woo Jung Jang, Duk Yong Choi, In Sang Jeon
Department of Pediatrics, Graduate School of Medicine, Gachon University, Incheon, Korea
Corresponding Author: In Sang Jeon ,Tel: +82-32-460-8382, Fax: +82-32-460-3224, Email:
Copyright © 2013 by The Korean Pediatric Society
Purpose: Anthracyclines have been utilized in the treatment of children with acute lymphoblastic leukemia (ALL). Recent studies have shown that anthracyclines may induce toxicity in the vascular endothelium. This study was performed using brachial artery reactivity (BAR) to evaluate vascular endothelial function in ALL patients who were treated with anthracycline chemotherapy.
Methods: We included 21 children with ALL who received anthracycline chemotherapy and 20 healthy children. The cumulative dose of anthracyclines in the ALL patients was 142.518.2/m2. The last anthracycline dose was administered to the patients 2 to 85 months prior to their examination using BAR. The diameter of the brachial artery was measured in both groups using echocardiography, and BAR was calculated as the percentage change in the arterial diameter after release of the cuff relative to the baseline vessel diameter.
Results: In the anthracycline-treated group, BAR was observed to be 3.4%3.9%, which was significantly lower than that observed in the control group (12.1%8.0%, P<0.05). The time elapsed after the last anthracycline treatment and the age at the time of treatment did not affect the change in BAR (P =0.06 and P =0.13, respectively).
Conclusion: These results provided evidence that treatment of ALL patients with anthracycline results in endothelial dysfunction. A larger cohort study and a longer follow-up period will be required to clarify the relationship between endothelial dysfunction resulting from anthracycline treatment for childhood ALL and occurrence of cardiovascular diseases later in life.
Keywords: Anthracycline | Vascular endothelium | Acute lymphoblastic leukemia | Child
PDF Links  PDF Links
Full text via DOI  Full text via DOI
  via Pubmed
Full text via PMC  Full text via PMC
via Pubreader  via PubReader
Download Citation  Download Citation
Supplementary Material  Supplementary Material
Prognostic factors and treatment of pediatric acute lymphoblastic leukemia  2017 May;60(5)
Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia  2011 March;54(3)
Increased vascular endothelial growth factor in children with acute Mycoplasma pneumoniae pneumonia and wheezing  2008 May;51(5)
Endocrine dysfunction and growth in children with medulloblastoma  2006 March;49(3)
The significance of vascular endothelial growth factor(VEGF) in children with asthma and pneumonia  2006 February;49(2)
Register for e-submission
Register here to access the e-submission system of Korean J Pediatr for authors and reviewers.
Manuscript Submission
To submit a manuscript, please visit the Korean J Pediatr e-submission management system at, read the Instructions for Authors, and log into the Korean J Pediatr e-submission system. For assistance with manuscript submission, please contact:
Free archive
Anyone may access any past or current articles without logging in.
Korean Pediatric Society Office
#1606, Seocho World Officetel, 19 Seoun-ro, Seocho-gu, Seoul 137-070, Korea
TEL : +82-2-3473-7305    FAX : +82-2-3473-7307   E-mail:
BrowseCurrent IssueFor Authors and ReviewersAbout
Copyright© The Korean Pediatric Society. All right reserved.